Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Koracevic GP, Lovic DB. Dihydropyridine calcium channel blocker should be mentioned for prevention of aortic consequences of arterial hypertension. J Hypertens 2012;30:1487. [DOI: 10.1097/hjh.0b013e328353ad88] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

For:	Koracevic GP, Lovic DB. Dihydropyridine calcium channel blocker should be mentioned for prevention of aortic consequences of arterial hypertension. J Hypertens 2012;30:1487. [DOI: 10.1097/hjh.0b013e328353ad88] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Number	Cited by Other Article(s)
1	Dihydropyridine calcium channel blocker should be mentioned for prevention of aortic consequences of arterial hypertension. J Hypertens 2012. [DOI: 10.1097/hjh.0b013e3283544838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Dihydropyridine calcium channel blocker should be mentioned for prevention of aortic consequences of arterial hypertension. J Hypertens 2012. [DOI: 10.1097/hjh.0b013e3283544838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]